A form of blood cancer known as mantle cell lymphoma is critically dependent on a protein that coordinates gene expression, such that blocking its activity with an experimental drug dramatically slows the growth of this lymphoma in preclinical tests, according to a study from Weill Cornell Medicine researchers. The discovery, reported Oct. 25 in the Journal
Researchers at the Keck School of Medicine of USC and the Cleveland Clinic Florida Research and Innovation Center have published new studies of GRP78, a protein implicated in both COVID-19 and multiple types of cancer, and a new drug that interferes with its effects. While vaccination can provide life-saving protection against COVID-19, scientists are
Glioblastomas (GBMs) are highly aggressive cancerous tumors of the brain and spinal cord. Brain cancers like GBM are challenging to treat because many cancer therapeutics cannot pass through the blood-brain barrier, and more than 90 percent of GBM tumors return after being surgically removed, despite surgery and subsequent chemo- and radiation therapy being the most
Researchers at the University of California, Irvine and the Italian Institute of Technology have developed a new molecule, ALY101, that shows promising anti-cancer activity against a wide range of tumor cell types and in mouse models of a common type of melanoma. The findings, “Structure-based Design of CDC42 Effector Interaction Inhibitors for the Treatment of
The hemostatic system in cancer The hemostatic system forms an integral part of the innate immune system and contributes to tumor growth and metastasis. Many malignancies are associated with a hyper-thrombotic state that derives foremost from tissue factor (TF), the initiator of the coagulation cascade, expressed by tumor cells and innate immune cells and stromal
Diffuse large B-cell lymphoma. Photograph by CoRus13, distributed under a CC BY-SA 4.0 license Aggressive and relatively common lymphomas called diffuse large B cell lymphomas (DLBCLs) have a critical metabolic vulnerability that can be exploited to trick these cancers into starving themselves, according to a study from researchers at Weill Cornell Medicine and Cornell’s Ithaca campus.
Cancer is the second leading cause of death in the United States, taking half a million lives each year. CAR T technology has successfully harnessed the human immune system to produce awe-inspiring cancer remission rates. CRISPR-mediated genome engineering has enabled new developments in CAR T cells to bypass logistical, technical, and immunological roadblocks, making the
A novel form of macrophage-based immunotherapy is effective at treating a broad spectrum of cancers, including those at advanced stages, according to a groundbreaking study led by Georgia State immunology professor Yuan Liu. Liu’s treatment works by leveraging macrophages, specialized white blood cells involved in the detection and elimination of cancer cells and other pathogens. Macrophages also activate
Their study outlines several treatments being investigated for the treatment of patients with myelofibrosis and other myeloproliferative neoplasms, generally after they have become resistant or intolerant to Janus kinase inhibition. A recent study outlines several treatments being investigated for the treatment of patients with myelofibrosis (MF) and other myeloproliferative neoplasms (MPNs), generally after they have become resistant or
Immunotherapy has unleashed a revolution in care for some cancer patients. But most immunotherapies help only a small subset of patients, meaning doctors often have to resort to a trial-and-error process to determine who might actually benefit from the novel treatments. Now, scientists have developed a new metric they believe can help predict whether patients will respond
